Skip to main content

Table 3 Summary of adverse events related to treatment with at least 10% incidence—by cohort

From: Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases

 

Overall

Cohort

HER2-negative (N = 9)

HER2-positive (N = 29)

Grade

Grade

N

1

2

3

1

2

3

4

AE name

 Hemoglobin

29 (76%)

4 (44%)

3(33%)

 

10 (34%)

11 (38%)

1 (3%)

 

 Fatigue

28 (74%)

1 (11%)

3(33%)

2(22%)

9 (31%)

9 (31%)

4 (14%)

 

 Platelets

28 (74%)

3 (33%)

3(33%)

 

6 (21%)

12 (41%)

3 (10%)

1 (3%)

 AST

23 (61%)

5 (56%)

1(11%)

 

15 (52%)

 

2 (7%)

 
 

22 (58%)

2 (22%)

1(11%)

 

3 (10%)

13 (45%)

3 (10%)

 

 Head/headache

20 (53%)

4 (44%)

  

10 (34%)

6 (21%)

  

 Hyperglycemia

18 (47%)

3 (33%)

1(11%)

 

12 (41%)

2 (7%)

  

 Leukocytes

18 (47%)

   

4 (14%)

14

  

 Nausea

17 (45%)

1 (11%)

1(11%)

 

13 (45%)

2 (7%)

  

 ALT

14 (37%)

3 (33%)

1(11%)

 

8 (28%)

 

2 (7%)

 

 Constipation

14 (37%)

3(33%)

1(11%)

 

7 (24%)

3 (10%)

  

 Neuropathy-sensory

14 (37%)

3(33%)

  

9 (31%)

2 (7%)

  

 Nose, hemorrhage

12 (32%)

1(11%)

  

9 (31%)

2 (7%)

  

 Alkaline phosphatase

11 (29%)

   

9 (31%)

2 (7%)

  

 Diarrhea w/o prior colostomy

11 (29%)

1(11%)

1(11%)

 

7 (24%)

2 (7%)

  

 Cough

9 (24%)

   

8 (28%)

1 (3%)

  

 Hypertension

9 (24%)

   

6 (21%)

2 (7%)

1 (3%)

 

 Alteration in bone age

8 (21%)

   

6 (21%)

2 (7%)

  

 Proteinuria

8 (21%)

1(11%)

  

6 (21%)

1 (3%)

  

 Extremity-limb, pain

7 (18%)

   

4 (14%)

2 (7%)

1 (3%)

 

 Alopecia

6 (16%)

 

1(11%)

  

4 (14%)

1 (3%)

 

 Hyponatremia

6 (16%)

   

5 (17%)

 

1 (3%)

 

 Joint, pain

6 (16%)

   

3 (10%)

2 (7%)

1 (3%)

 

 Vomiting

6 (16%)

2(22%)

1(11%)

 

2 (7%)

1 (3%)

  

 Allergic reaction

5 (13%)

   

1 (3%)

4 (14%)

  

 Back, pain

5 (13%)

   

4 (14%)

1 (3%)

  

 Dizziness

5 (13%)

   

2 (7%)

3 (10%)

  

 Infection Grade 0–2, upper airway

5 (13%)

   

4 (14%)

1 (3%)

  

 Left ventricular systolic dysfunction

5 (13%)

    

5 (17%)

  

 Pain-other

5 (13%)

1(11%)

1(11%)

 

1 (3%)

2 (7%)

  

 Rectum, hemorrhage

5 (13%)

   

4 (14%)

1 (3%)

  

 Bone, pain

4 (11%)

   

4 (14%)

   

 CNS, hemorrhage

4 (11%)

1(11%)

1(11%)

 

2 (7%)

   

 Constitutional, other

4 (11%)

   

3 (10%)

1 (3%)

  

 Creatinine

4 (11%)

2(22%)

  

2 (7%)

   

 GI-other

4 (11%)

   

4 (14%)

   

 Hypocalcemia

4 (11%)

   

4 (14%)

   

 Hypokalemia

4 (11%)

1(11%)

  

3 (10%)

   

 Metabolic/laboratory-other

4 (11%)

2(22%)

1(11%)

 

1 (3%)

   

 Skin-other

4 (11%)

2(22%)

  

1 (3%)

1 (3%)

  

 Throat/pharynx/larynx, pain

4 (11%)

   

4 (14%)

   
  1. Abbreviations: AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase, CNS central nervous system, GI gastrointestinal, HER2 human epidermal growth factor receptor 2